SGP Fundamental Research Investment Analysis, Schering-Plough Corp.

Stock Research iPhone App Coming Soon to the AppStore Click here to register for newsletter and report access
close nav

Schering-Plough Corporation (SGP)

The Razor's Edge

2-Year Price History

Recent Price
(12/3/2008)
$16.50
52-Week Price
$11.97 - $27.81
Market Capitalization
$26.8 Billion
Dividend Yield
1.60%
Most Recent Dividend
$0.25

About Schering-Plough Corp.

Schering-Plough Corporation is considered to operate in the Healthcare sector. They specifically operate in the Drug Manufacturers/Major business segment contained within the Drugs industry.

The Company discovers, develops and manufactures pharmaceuticals for three customer markets - human prescription, animal health, and consumer.

Ockham's Rating

Rating Specific Information Withheld Premium Access Only

SGP Revenue

For a long time, value investors have used the current share price relative to sales per share levels as an important valuation tool. We utilize a historical weighted average methodology that treats recent years more importantly in the calculation. When looking at SGP through this framework, we can see that our weighted average historical high and low Price to Sales per share ratios over the last 10 years are 4.04x and 2.47x respectively.

Utilizing this range we can see that SGP’s current Price to Sales per share ratio of 1.40x is significantly below its average levels historically. In fact, with a current price of $16.81, SGP is a full 57% below its average Price to Sales ratio at comparable sales levels. This is a rare occurrence and, when taken in context of the other areas of our analysis, can be a strong positive for our outlook for SGP.

SGP Cash Earnings

Cash Earnings is always one of the most important factors to review for a company and, more importantly, an investment in a stock. SGP is significantly below its historical average multiple of cash earnings as calculated by Ockham. Similar to our analysis of sales per share, Ockham looks at the last 10 years of cash earnings levels for SGP to identify where the current high and low price levels have been historically in relation to profit per share. Again, we utilize a weighted average methodology which relies more heavily on recent years of data. This weighted average framework provides us with an average high Price to Cash Earnings ratio per share of 35.05 and a 22.75 low over the same period.

Now that SGP’s current price is $16.81 and its Price to Cash Earnings ratio is 5.17, we are very positive on its outlook from the cash earnings perspective. In fact, SGP is now trading a full 83% below its average historical Price to Cash Earnings ratio at these profit per share levels. When our clients ask us why SGP has great long term potential, the Cash Earnings levels to current stock is one of our primary reasons. But naturally, now we need for the overall market to recognize this disparity.

SGP Dividends

A strong dividend payment history is looked upon as a favorable characteristic on a company’s future and potentially can receive a positive Ockham rating. That being said, we don't require dividend payments for company's whose management has elected to forgo them entirely.

When reviewing dividend yields for SGP, we compare the historic high and low levels over the past, which is similar to our evaluation of Sales and Cash Earnings per share. Paying a dividend is not necessary for any company, but changes in dividend often can lend clues as to the health of the business. A rising dividend is a strong sign for an established company, as it reflects management's confidence in the company. SGP’s estimated annual dividend is $0.26 resulting in a current dividend yield of 1.55%. The highest dividend yield from SGP over recent history was 4.17% while the lowest dividend yield was 0.74%. It is never a good sign for a company to pay significantly lower dividends, in this case 36.86% below the median yield. Although, dividends are a relatively small portion of our analysis framework, we still see this as a negative factor.

Peer Comparison

:

Schering-Plough Corp. Industry Grouping

(12/3/2008)
Company Ticker Market Cap (Ml) Latest
Price
Price/Cash Earnings Price/Sales 5-Yr. Rev.
Growth Rate
5-Yr.
Avg. ROE.
Current 10-Yr. Range* Current 10-Yr. Range*
Peer Company Averages (not incuding SGP) 12.53 11.10 » 257.51 3.68 6.37 » 40.72 28.47% 13.33%
*10 year range does not include current year values
Eli Lilly & Company LLY $39.8 Billion $34.97 6.53 5.93 » 36.16 1.79 5.61 » 25.45 10.96% 21.42%
Teva Pharmaceutical Industries Limited TEVA $35.2 Billion $43.41 11.69 10.03 » 41.02 2.83 2.33 » 22.23 30.16% 12.80%
Schering-Plough Corp. SGP $26.8 Billion $16.50 5.17 3.90 » 107.95 1.40 4.55 » 20.19 4.51% 4.29%
Novo Nordisk A/S NVO $26.6 Billion $51.78 14.19 8.13 » 30.72 3.25 3.33 » 22.24 18.17% 21.46%
Celgene Corp. CELG $24.1 Billion $52.60 18.74 20.84 » 972.00 7.22 16.36 » 100.87 59.60% 7.38%
Genzyme Corp. GENZ $17.2 Billion $63.56 11.49 10.58 » 207.66 3.31 4.19 » 32.80 23.46% 3.57%
Ockham Ratings & Analysis Report
Quarterly Access (100 Days) to:
Schering-Plough Corporation (SGP)
Price$20
Ockham Research will send you updated investment ratings and research report access as new reports or ratings are published for a full 100 days from the purchase date. Rather than just one report or rating, Ockham Research is committed to updating our clients on every stock they care about on an ongoing basis.

For more information on all our product offerings, click here

Community Discussion

  • Be the first to Comment!

Key Fundamentals

SGP - Schering-Plough Corporation Fundamentals
Price (12/3/2008) $16.50
Volume (12/3/2008) 21.6 Million
10 Day Average Volume 16.8 Million
13 Week Price Range $11.97 - $20.00
52 Week Price Range $11.97 - $27.81
LTM Revenue $17.9 Billion
 
Shares Outstanding (12/2007) 1.6 Billion
Market Capitalization $26.8 Billion
Shares Held By Institutions 1.4 Billion
Insitutional Holders 986
% Shares Held By Institutions 83.10%
Earnings Per Share (EPS) ($1.04)
P/E Ratio n/a
Book Value Per Share $5.30
 
Gross Margin 71.80%
Quarterly Dividend 0.26
Dividend Yield 1.60%
Beta 1.11
Fiscal Year Ends December